Zena-Huancas Paola, Leon-Jimenez Franco, Bryce-Alberti Mayte, Portmann-Baracco Arianna
Internal Medicine, Hospital de la Amistad Perú-Corea Santa Rosa, Piura, Peru.
Internal Medicine, Hospital de la Amistad Perú-Corea Santa Rosa; Facultad de Medicina, Universidad Señor de Sipán, Piura, Peru.
Lung India. 2021 Nov-Dec;38(6):574-576. doi: 10.4103/lungindia.lungindia_766_20.
Based on the pathophysiological characterization of COVID-19, initial studies suggested the use of tocilizumab (TCZ), a recombinant humanized monoclonal antibody of the immunoglobulin G1 class, for management of the cytokine storm witnessed in severe cases. Thus, we decided to present a case series of 18 patients with severe COVID-19 treated with TCZ at our hospital. Our results coincide with the fact that the routine use of TCZ in severe COVID-19 is not robustly supported. We believe that the efficacy and safety of this drug and other related molecules should be validated in large randomized clinical trials.
基于新型冠状病毒肺炎（COVID-19）的病理生理特征，初步研究表明，可使用托珠单抗（TCZ）（一种免疫球蛋白G1类重组人源化单克隆抗体）来治疗重症病例中出现的细胞因子风暴。因此，我们决定展示我院收治的18例接受托珠单抗治疗的重症COVID-19患者的病例系列。我们的结果与以下事实相符：在重症COVID-19中常规使用托珠单抗并没有得到有力支持。我们认为，这种药物和其他相关分子的疗效和安全性应在大型随机临床试验中得到验证。
